Opening book details…
Can I read Comparison of Reduced Intensity Conditioning Regimens Used in Patients Undergoing Hematopoietic Stem Cell Transplantation for Myelofibrosis on EtoBox?
Comparison of Reduced Intensity Conditioning Regimens Used in Patients Undergoing Hematopoietic Stem Cell Transplantation for Myelofibrosis by Tania Jain; Katie L. Kunze; M’hamed Temkit; Daniel K. Partain; Mrinal S. Patnaik; James L. Slack; Nandita Khera; William J. Hogan; Vivek Roy; Pierre Noel; Jose F. Leis; Lisa Z. Sproat; Veena Fauble; Ruben A. Mesa; Jeanne Palmer is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.
What is Comparison of Reduced Intensity Conditioning Regimens Used in Patients Undergoing Hematopoietic Stem Cell Transplantation for Myelofibrosis about?
The aim of this study is to compare clinical outcomes of patients who underwent allogeneic stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) using either Busulfan Fludarabine (BuFlu), Fludarabine Bischlorethyl-nitroso-urea/ carmustine Melphalan (FBM) or Fludarabine Melphalan (FluMel) regimens. Sixty-one patients were identified who underwent HCT with one of these RIC regimens. Overall survival (OS) was not different in the 3 groups. However, 100% donor chimerism was seen in more frequently at day +30 and day +100 in patients who received FBM or FluMel than BuFlu, in both CD3 and CD33 fractions. For instance, 100% donor chimerism in CD33 fraction was present in 100% patients in FBM cohort, 90% in FluMel cohort while 44% in BuFlu cohort at day +100. Acute graft-versus host disease, grade 2-4 and grade 3-4, was not statistically different in the 3 groups (BuFlu 47 and 35%, FBM 68 and 27%, FluMel 68 and 46%; p = 0.31 and 0.45). Relapses and non-relapse mortality was also not statistically significantly different. Our study shows similar OS with these 3 RIC regimens in myelofibrosis; although donor chimerism at day +30 and day +100 was better in
Who reads Comparison of Reduced Intensity Conditioning Regimens Used in Patients Undergoing Hematopoietic Stem Cell Transplantation for Myelofibrosis?
It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.
- Author
- Tania Jain; Katie L. Kunze; M’hamed Temkit; Daniel K. Partain; Mrinal S. Patnaik; James L. Slack; Nandita Khera; William J. Hogan; Vivek Roy; Pierre Noel; Jose F. Leis; Lisa Z. Sproat; Veena Fauble; Ruben A. Mesa; Jeanne Palmer
- Publisher
- Nature Publishing Group; John Wiley and Sons; Springer Science and Business Media LLC; Wiley (Blackwell Publishing); Wiley-Blackwell; Society for Mining, Metallurgy and Exploration Inc.; Wiley; Research Square (ISSN 0007-1188)
- Published
- 2018
- Language
- EN
- Field
- Biochemistry, Genetics and Molecular Biology (Life Sciences)